Interaction Checker

Wechselwirkungen von Dasatinib

Dasatinib (Sprycel, Phyrago) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 152 dokumentierte Wechselwirkungen: 69 schwerwiegende, 30 mittelschwere, 53 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (69)

  • AmiodaronAntiarrhythmikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Antazida (Tums, Maalox, Mylanta)Rezeptfreies PräparatSchwerwiegend

    Antacids: Avoid concomitant use. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • AprepitantCYP3A4-HemmerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • ArmodafinilZNS-StimulansSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Atazanavirantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • BosentanCYP3A4-InduktorSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • CarbamazepinAntiepileptikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • CenobamatAntiepileptikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • CiclosporinImmunsuppressivumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • CimetidinH2-BlockerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • ClarithromycinMakrolid-AntibiotikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • ClobazamBenzodiazepinSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Darunavirantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Darunavir und Cobicistatantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • DeferasiroxEisenpräparatSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • DexamethasonKortikosteroidSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • DiltiazemCalciumkanalblockerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • DronedaronAntiarrhythmikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Efavirenzantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Efavirenz, Lamivudin und Tenofovirantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • ErythromycinMakrolid-AntibiotikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • EslicarbazepinAntiepileptikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Etravirinantiretrovirales ArzneimittelSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • EverolimusImmunsuppressivumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • FluconazolAzol-AntimykotikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Fosamprenavirantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • FosaprepitantCYP3A4-HemmerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • FosphenytoinAntiepileptikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • GriseofulvinAntimykotikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Ibuprofen und FamotidinNSARSchwerwiegend

    Intervention Concomitant administration of ibuprofen and famotidine tablet is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. (Fachinformation zu Ibuprofen und Famotidin, Arzneimittelwechselwirkungen)

  • ImatinibCYP3A4-HemmerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • IsoniazidAntibiotikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • ItraconazolAzol-AntimykotikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • IvacaftorCYP3A4-HemmerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • KetoconazolAzol-AntimykotikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Lenacapavirantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Lopinavir und Ritonavirantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • LorlatinibCYP3A4-InduktorSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • MifepristonCYP3A4-HemmerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • MirabegronBeta-Adrenozeptor-AgonistSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • MitapivatCYP3A4-InduktorSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • MitotanCYP3A4-InduktorSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • ModafinilZNS-StimulansSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • NafcillinPenicillin-AntibiotikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • NatriumhydrogencarbonatAntazidumSchwerwiegend

    Antacids: Avoid concomitant use. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • NefazodonAntidepressivumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Nevirapinantiretrovirales ArzneimittelSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Nirmatrelvir und RitonavirVirostatikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Omeprazol und NatriumhydrogencarbonatProtonenpumpenhemmer (PPI)Schwerwiegend

    Antacids: Avoid concomitant use. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • OxcarbazepinAntiepileptikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • PalbociclibCYP3A4-HemmerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • PerampanelAntiepileptikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • PhenobarbitalBarbituratSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Phentermin und TopiramatZNS-StimulansSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • PhenytoinAntiepileptikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • PosaconazolAzol-AntimykotikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • PrimidonAntiepileptikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • RanolazinQT-verlängerndes ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • RifabutinAntibiotikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • RifampicinAntibiotikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • RifapentinAntibiotikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • Ritonavirantiretrovirales ArzneimittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • SuvorexantSchlaf- und BeruhigungsmittelSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • SuzetriginCYP3A4-InduktorSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • TicagrelorThrombozytenaggregationshemmerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • TopiramatAntiepileptikumSchwerwiegend

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • VerapamilCalciumkanalblockerSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

  • VoriconazolAzol-AntimykotikumSchwerwiegend

    Avoid concomitant use of strong CYP3A4 inhibitors. (Fachinformation zu Dasatinib, Arzneimittelwechselwirkungen)

Mittelschwere Wechselwirkungen (30)

  • AdenosinAntiarrhythmikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • ApixabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • ArgatrobanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • BivalirudinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • ChinidinAntiarrhythmikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • DabigatranAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • DexlansoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Dexlansoprazol, Arzneimittelwechselwirkungen)

  • DigoxinDigitalisglykosidMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • DisopyramidAntiarrhythmikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • DofetilidAntiarrhythmikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • EdoxabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • EnoxaparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • EsmololBetablockerMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • EsomeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole… (Fachinformation zu Esomeprazol, Arzneimittelwechselwirkungen)

  • FlecainidAntiarrhythmikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • FondaparinuxAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • HeparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • IbutilidAntiarrhythmikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • LansoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Lansoprazol, Arzneimittelwechselwirkungen)

  • LidocainLokalanästhetikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Lidocain und PrilocainLokalanästhetikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • MexiletinAntiarrhythmikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • OmeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Omeprazol, Arzneimittelwechselwirkungen)

  • PantoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Pantoprazol, Arzneimittelwechselwirkungen)

  • ProcainamidAntiarrhythmikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • PropafenonAntiarrhythmikumMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • RabeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Rabeprazol, Arzneimittelwechselwirkungen)

  • RivaroxabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • SotalolBetablockerMittelschwer

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • WarfarinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

Geringfügige Erwähnungen (53)

  • AcetazolamidCarboanhydrasehemmerGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Amiloridkaliumsparendes DiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Atenolol und ChlortalidonBetablockerGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Azelastin und FluticasonAntihistaminikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • BeclometasonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Benazepril und HydrochlorothiazidACE-HemmerGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • BetamethasonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Bisoprolol und HydrochlorothiazidBetablockerGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • BudesonidKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Budesonid und FormoterolKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • BumetanidSchleifendiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Candesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlorothiazidThiaziddiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlortalidonThiaziddiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclesonidKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • ClobetasolKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • DeflazacortKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • DesonidKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Enalapril und HydrochlorothiazidACE-HemmerGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • EplerenonAldosteronantagonistGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • EtacrynsäureSchleifendiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • FludrocortisonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • FlunisolidKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • FluocinonidKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • FluticasonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Fluticason und SalmeterolKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Fosinopril und HydrochlorothiazidACE-HemmerGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • FurosemidSchleifendiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • HalobetasolKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrochlorothiazidThiaziddiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrocortisonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • IndapamidThiaziddiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Irbesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Lisinopril und HydrochlorothiazidACE-HemmerGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Losartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • MethylprednisolonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • MetolazonThiaziddiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Metoprolol und HydrochlorothiazidBetablockerGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • MometasonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan, Amlodipin und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Olopatadin und MometasonAntihistaminikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisolonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Quinapril und HydrochlorothiazidACE-HemmerGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • SpironolactonAldosteronantagonistGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Spironolacton und HydrochlorothiazidAldosteronantagonistGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Telmisartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • TorasemidSchleifendiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • TriamcinolonKortikosteroidGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Triamterenkaliumsparendes DiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Triamteren und Hydrochlorothiazidkaliumsparendes DiuretikumGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Valsartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Geringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

Prüfen Sie Dasatinib gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.